"
The Supreme Court is set to hear arguments on whether the abortion pill mifepristone should remain on the market, with the focus on the FDA\'s drug approval process; the Biden administration is appealing lower court rulings that restricted access to the pill. The case involves Texas-based rulings that questioned the FDA\'s approval of mifepristone and concerns around loosened restrictions implemented in 2016, such as remote prescribing and extended usage up to 10 weeks of pregnancy. The pharmaceutical industry supports the FDA, warning against judicial interference in the drug approval process.
By MARK SHERMAN
NPR
NBC
https://www.theguardian.com/profile/chris-stein,https://www.theguardian.com/profile/lauren-gambino
Washington Post
The Huffington Post
NBC